Dr. Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine adjuvant company, with headquarters in Lincoln, NE. He has more than 25 years’ experience developing innovative products in the biotechnology industry. He has led development activities to support more than 100 Investigational New Drug (IND) Applications, and developed four products, 2 vaccines and 2 antibiotics, that eventually received FDA or EMA approval. He has held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax.
Dr. Martin received a bachelor’s degree with honors from the University of Nebraska at Kearney, and an MD degree from the University of Nebraska College of Medicine. He was a resident in Pediatrics at the University of Nebraska Medical Center and was a post-doctoral fellow in Molecular Microbiology and Pediatric Infectious Diseases at Washington University in St. Louis.
Prof. Giancarlo Pruneri
Prof. Pruneri is a full professor in pathology at the University of Milan School of Medicine, and is Chair of the Department of Pathology and Laboratory Medicine with the National Cancer Institute of Milan, a comprehensive cancer centre fully equipped for translational research and innovative care, including a molecular lab for next-generation sequencing. He is devoted to translational research programs, currently focused in breast pathology, sustained by several national and international peer-reviewed grants, resulting in more than 280 publications yielding to a H-index of 55. He is involved in several international networks, including the International Breast Cancer Study Group (IBCSG), in which he was appointed as chair of the Translational Research Working Group and in the International Immuno-Oncology Working Group, which is focused on the validation of biomarkers for immunotherapy.